AIM ImmunoTech Inc. — Director's Dealing 2017

Mar 31, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2016-08-24

Reporting Person: Appelrouth Stewart (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-08-24	Common Stock	P	15750	$2.21	Acquired	15750	Direct

Footnotes

F1: Shares and prices have been adjusted to give retroactive effect to the 1 for 12 reverse stock split effected on 8/29/16.

F2: This transaction was executed in multiple trades at prices ranging from $2.16 to $2.22. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.